CLINICAL HANDBOOK OF SCHIZOPHRENIA

Index 643side effectsin adolescents, 488potential for, 169twith valproate, 187–188weight gain and, 172Older adultsabsence in pharmacotherapytrials, 392antipsychotics for, 393, 395atypical antipsychotics and,392, 395See also Late-life schizophreniaOlmstead v. L. C., 295–296Omega-3 polyunsaturated fattyacids, 193–194Operant conditioning, incognitive rehabilitation, 254Opportunity costs, 509–510Oregon Quality of Life Scale,584, 584tOrganizational change, phases of,541–542Orthostatic hypotension,antipsychotic-induced, 175–176Outcomesafter deinstitutionalization, 567gender differences in, 578–579good, defined, 561measures of, 560quality of life as criterion of,587–589Outreach programs, homelessnessand, 415, 420Overarousal, symptoms of, 448Overdiagnosis, in AfricanAmericans, 616–617Overdosage, antipsychotic, 176Overlearning, 243Oxazepam, for catatonia, 190PACE. See Personal Assessmentand Crisis Evaluation ClinicPaliperidone, dosing of, 165tPanic disordercognitive therapy for, 228PACE approach to, 386Parahippocampal gyrus, 48Paranoia, 78healthy, in African Americans,617positive beliefs about, 226–227,232Paraphrenia, late, 17Parenthood, 471–480epidemiology and socialcontext, 471–472and loss of custody, 474pharmacotherapy and, 474–478schizophrenia treatment and,474–479schizophrenia’s impact on, 472and schizophrenia’s impact onchildren, 473Parenting assessment,components of, 477Parentsbarriers to treating, 478–479psychosocial rehabilitation and,477–478Parietal lobe, changes in, 50Parkinsonism, antipsychoticinduced,169–170, 392Parkinson’s disease, clozapine for,180Passivity experiences, 83Paternal age, 20Pathways to Housing, 418Patient beliefsabout traumatic experiences,235–236advantages and disadvantages,231–233alternative explanations for,233–234assessment of, 230and content of voices, 235core/procedural, 230evidential analysis of, 233See also Cognitive-behavioraltherapyPatient capacity, defined, 521–522Patient Outcomes ResearchTeam, 150tPCP. See PhencyclidinePeer-to-Peer program, 303Perphenazine (Trilafon)cost-effectiveness of, 512discontinuation of, 168dosing of, 163tPersistent symptoms, copingstrategies for, 273–274, 274tPersonal Assessment and CrisisEvaluation Clinic, 380criteria for ultra high risk,381–382general treatment measures,382–383psychological treatments, 383–387Personal planning, 322Personal therapy, 275tPET. See Positron emissiontomographyPharmacotherapyfor African Americans, 620–622, 620tcost-effectiveness of, 511–512for first-episode psychosis,371–372for parents with schizophrenia,474–476See also Antipsychotics;Medications; specificagentsPharmacotherapy trials, absenceof older adults in, 392Phencyclidine, 8Phenotype, research on, 56tPhobias, 78Physical abuse, inmate history of,359Physical restraints, 345Pill organizers, 271Placebo controls, ethical use of,629Planum temporale, 49PMI. See Postmortem indexPneumoencephalography, 9Police departments, collaborationwith mental healthprofessionals, 527–528Policy changes, evidence-basedpractice and, 547Polydipsia, co-occurring, 132–133Polypharmacyin children, 487creeping, 443drug interactions and, 344Positive and Negative SyndromeScale, 401Positive symptoms, 85–87definitions of, 117–118disorganization dimension,86–87psychotic dimension, 85–86lamotrigine and, 189PACE approach to, 385spiritual/religious practices and,598treatment of, 149t, 151Positron emission tomography,10Postmortem index, 52Posttraumatic stress syndrome.See PTSDPractice Guideline for theTreatment of Patients withSchizophrenia, 150tPrader–Willi syndrome, featuresof, 439Pre-/perinatal influences. SeeObstetric complicationsPrefrontal cortexchanges in, 36–37neuron maldistribution in,51